NCT04902183View on ClinicalTrials.gov

Safety and Efficacy of Exosomes Overexpressing CD24 in Two Doses for Patients With Moderate or Severe COVID-19

PHASE2UnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 9, 2021

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Covid19
Interventions
DRUG

CovenD24

The drug will be administrated once daily for 5 days

Trial Locations (3)

11527

NOT_YET_RECRUITING

"3rd Department of Medicine, Sotiria Thoracic Diseases General Hospital of Athens", Athens

NOT_YET_RECRUITING

"7th Respiratory Medicine Department, Sotiria Thoracic Diseases General Hospital of Athens", Athens

12462

RECRUITING

Attikon University Hospital, Athens

Sponsors
All Listed Sponsors
collaborator

OBCTCD24 Ltd

UNKNOWN

collaborator

Elpen Pharmaceutical Co. Inc.

INDUSTRY

lead

Athens Medical Society

OTHER